New frontiers in inflammation: from translational research to clinic
Year: 2022

OBJECTIVE: current paediatric treatment protocols for Hodgkin lymphoma (HL) include a combination of risk-adapted multiagent chemotherapy together with low-dose involved-field radiotherapy. These therapeutic procedures can trigger an inflammatory response by causing necrosis and tissue injury that stimulate late complications. Hodgkin lymphoma and acute lymphoblastic leukaemia survivors show an increased risk of long-term complications, particularly cardiovascular diseases and malignant neoplasm